Zhejiang Shengda Pharm (603079) - Total Assets
Based on the latest financial reports, Zhejiang Shengda Pharm (603079) holds total assets worth CN¥2.15 Billion CNY (≈ $314.07 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Zhejiang Shengda Pharm for net asset value and shareholders' equity analysis.
Zhejiang Shengda Pharm - Total Assets Trend (2012–2024)
This chart illustrates how Zhejiang Shengda Pharm's total assets have evolved over time, based on quarterly financial data.
Zhejiang Shengda Pharm - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhejiang Shengda Pharm's total assets of CN¥2.15 Billion consist of 39.7% current assets and 60.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 17.7% |
| Accounts Receivable | CN¥141.79 Million | 7.9% |
| Inventory | CN¥197.54 Million | 11.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥225.58 Million | 12.6% |
| Goodwill | CN¥10.91 Million | 0.6% |
Asset Composition Trend (2012–2024)
This chart illustrates how Zhejiang Shengda Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Zhejiang Shengda Pharm worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Shengda Pharm's current assets represent 39.7% of total assets in 2024, a decrease from 43.5% in 2012.
- Cash Position: Cash and equivalents constituted 17.7% of total assets in 2024, up from 14.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, a decrease from 25.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 12.6% of total assets.
Zhejiang Shengda Pharm Competitors by Total Assets
Key competitors of Zhejiang Shengda Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.07 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
Zhejiang Shengda Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.41 | 2.78 | 2.46 |
| Quick Ratio | 3.51 | 1.93 | 1.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥742.60 Million | CN¥426.98 Million | CN¥522.39 Million |
Zhejiang Shengda Pharm - Advanced Valuation Insights
This section examines the relationship between Zhejiang Shengda Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.38 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | 3.8% |
| Total Assets | CN¥1.79 Billion |
| Market Capitalization | $441.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Shengda Pharm's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Zhejiang Shengda Pharm's assets grew by 3.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zhejiang Shengda Pharm (2012–2024)
The table below shows the annual total assets of Zhejiang Shengda Pharm from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.79 Billion ≈ $261.25 Million |
+3.85% |
| 2023-12-31 | CN¥1.72 Billion ≈ $251.57 Million |
+3.87% |
| 2022-12-31 | CN¥1.66 Billion ≈ $242.21 Million |
-6.21% |
| 2021-12-31 | CN¥1.76 Billion ≈ $258.25 Million |
+3.76% |
| 2020-12-31 | CN¥1.70 Billion ≈ $248.89 Million |
+10.98% |
| 2019-12-31 | CN¥1.53 Billion ≈ $224.27 Million |
+22.34% |
| 2018-12-31 | CN¥1.25 Billion ≈ $183.31 Million |
+27.05% |
| 2017-12-31 | CN¥985.98 Million ≈ $144.28 Million |
+32.99% |
| 2016-12-31 | CN¥741.37 Million ≈ $108.49 Million |
+18.78% |
| 2015-12-31 | CN¥624.13 Million ≈ $91.33 Million |
+13.84% |
| 2014-12-31 | CN¥548.27 Million ≈ $80.23 Million |
+8.55% |
| 2013-12-31 | CN¥505.09 Million ≈ $73.91 Million |
-0.46% |
| 2012-12-31 | CN¥507.42 Million ≈ $74.25 Million |
-- |
About Zhejiang Shengda Pharm
Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin, polylysine, and natamycin; and intermediate APIs. The company was incorporated in 1999 and is headquartered in Tiantai, China.